About Lyka Generics Limited
Data last updated:
Lyka Generics Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Lyka Exports Limited. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 16 March 2013 and has been in existence for over 13 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U85100MH2013PLC241035. Its GSTIN is 27AACCL4481D1ZM (Maharashtra).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It was formerly known as Lyka Animal Healthcare Limited. It is led by directors including Kunal Narendra Gandhi and Narendra Chimanlal Rathod.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2024, the company reported a revenue of ₹4.13 Cr, a growth of 46% compared to the previous year. For the same year it recorded a net profit of ₹61.06 Lakh (net margin 14.8%) and EBITDA of ₹1.45 Cr (EBITDA margin 35.1%). Revenue has grown at a compounded annual rate (CAGR) of 33% over three years.
As per MCA filings, the company has open charges of ₹4.7 Cr and satisfied charges of ₹36.82 Lakh on record. Court records list 1 case involving the company.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lykalabs.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address6 Floor – Grd Plot – 79 Himalaya House Ramabai Ambedkar Marg Crawford Market, Fort, Mumbai, Maharashtra, India – 400001
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Lyka Generics Limited
The main business activity of Lyka Generics is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 46 | Wholesale trade, except of motor vehicles and motorcycles | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Lyka Generics Limited FY 2025 filings available
Lyka Generics Limited reported revenue of ₹4.13 Cr (up 46% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Lyka Generics Limited
Revenue has grown at a compounded annual rate (CAGR) of 33% over three years, including 46% growth in the latest year. EBITDA rose 49% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Lyka Generics Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹1.45 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹61.06 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Lyka Generics Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 35.1% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 14.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Lyka Generics are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Lyka Generics Limited
Lyka Generics Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Lifeflash Healthcare Private Limited | ₹4.14 Cr (FY 2025) | •••• | •••• | 28.0% | •••• | Patna, Bihar, India |
| Moti Research and Diagnostics Limited | ₹4.14 Cr (FY 2024) | •••• | •••• | -12.0% | •••• | Unnao, Uttar Pradesh, India |
| Sree Jayam Ortho and Multi-Speciality Hospital Private Limited | ₹4.14 Cr (FY 2024) | •••• | •••• | 2.0% | •••• | Salem, Tamil Nadu, India |
| Destiny Private Limited | ₹4.13 Cr (FY 2021) | •••• | •••• | 0.0% | •••• | Kolakta, West Bengal, India |
| Global Nutraceuticals Private Limited | ₹4.13 Cr (FY 2024) | •••• | •••• | 27.0% | •••• | Hosur, Tamil Nadu, India |
| Lyka Generics Limited this company | ₹4.13 Cr (FY 2024) | •••• | •••• | 46.0% | •••• | Mumbai, Maharashtra, India |
| Alcare Laboratories Private Limited | ₹4.13 Cr (FY 2025) | •••• | •••• | 38.0% | •••• | Delhi, India |
| A.V. Distributors Hub Private Limited | ₹4.13 Cr (FY 2025) | •••• | •••• | 140.0% | •••• | Indore, Madhya Pradesh, India |
| Symbiosis Bioscience Private Limited | ₹4.13 Cr (FY 2025) | •••• | •••• | 12.0% | •••• | Ahmedabad, Gujarat, India |
| Niketas Global Trade Private Limited | ₹4.12 Cr (FY 2024) | •••• | •••• | 1008.0% | •••• | Chennai, Tamil Nadu, India |
| Dr. Cure Pharmaceuticals (India) Private Limited | ₹4.11 Cr (FY 2025) | •••• | •••• | -2.0% | •••• | Bangalore, Karnataka, India |
Peers are the five companies nearest above and the five nearest below Lyka Generics by revenue in the Pharma industry (Pharma Retail and Distribution), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Lyka Generics Limited
Lyka Generics Limited is audited by D. KOTHARY & CO for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| D. KOTHARY & CO | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Lyka Generics Limited
Lyka Generics has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kunal Narendra Gandhi Also directs: Lyka Labs Limited, Relic Technologies Limited, Hiralaxmi Multitrade Private Limited and 1 more | Director | 16 Mar 2013 | 13 Years 6 Months | Current |
| Narendra Chimanlal Rathod | Director | 10 Oct 2022 | 3 Years 11 Months | Current |
| Alisha Kunal Gandhi | Director | 01 Aug 2019 | 7 Years 2 Months | Current |
Ownership and Shareholding of Lyka Generics Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Lyka Generics Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 May 2024 | Axis Bank Limited | ₹2.45 Cr | Open |
| 03 Mar 2023 | Axis Bank Limited | ₹2.25 Cr | Open |
| 28 Jan 2020 | Others | ₹36.82 Lakh | Satisfied |
Total charge records: 3 View all charges
Legal Cases of Lyka Generics Limited
Lyka Generics Limited has 1 court case on record: 1 where it is another party. All case is disposed. Status as checked on 02 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 0 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Sirmaur, Himachal Pradesh | Cheque dishonour complaint | Company is another party | Disposed |
Full case history
All 1 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Lyka Generics Limited
Employment history and EPFO contributions of people linked to Lyka Generics.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Lyka Generics Limited
Lyka Generics Limited has 7 board changes on record since 2013: 3 appointments and 4 cessations. The latest: Narendra Chimanlal Rathod ceased to be Additional Director on 28 Sep 2023.
2 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Lyka Generics Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Lyka Generics Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Lyka Generics Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Lyka Generics Limited
Lyka Generics has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCL4481D1ZM | Maharashtra | Active | 13 Aug 2019 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Lyka Generics Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lyka Generics Limited
Lyka Generics is an active public limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 16 March 2013 (13+ years old) and is registered under CIN U85100MH2013PLC241035.
Lyka Generics reported revenue of ₹4.13 Cr for FY 2024 (up 46% YoY).
Lyka Generics has 3 current directors:
- Kunal Narendra Gandhi - Director
- Narendra Chimanlal Rathod - Director
- Alisha Kunal Gandhi - Director
Lyka Generics reported a net profit of ₹61.06 Lakh (net margin 14.8%) and EBITDA of ₹1.45 Cr (EBITDA margin 35.1%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Lyka Generics is 33% over three years. In the latest year (FY 2024) revenue rose 46%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Lyka Generics is 27AACCL4481D1ZM, registered in Maharashtra.
The CIN (Corporate Identification Number) of Lyka Generics is U85100MH2013PLC241035. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Lyka Generics has 1 court case on record.
Lyka Generics was incorporated on 16 March 2013, making it 13+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Lyka Generics by revenue are Lifeflash Healthcare Private Limited, Moti Research and Diagnostics Limited, Sree Jayam Ortho and Multi-Speciality Hospital Private Limited, Destiny Private Limited, Global Nutraceuticals Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution).
Narendra Chimanlal Rathod ceased to be Additional Director on 28 Sep 2023. Narendra Chimanlal Rathod was appointed as Director on 10 Oct 2022. Nehal Gandhi Narendra ceased to be Director on 10 Oct 2022. Lyka Generics has 7 board changes on record in total.